Oragenics Announces Board and Executive Changes
Ticker: OGEN · Form: 8-K · Filed: Sep 20, 2024 · CIK: 1174940
Sentiment: neutral
Topics: management-change, compensation
TL;DR
Oragenics shakes up the board and exec comp. Big changes coming?
AI Summary
Oragenics, Inc. announced on September 19, 2024, changes in its board of directors and executive compensation arrangements. The filing details the departure of certain officers and directors, the election of new directors, and updates to compensatory plans.
Why It Matters
Changes in board composition and executive compensation can signal shifts in company strategy or governance, potentially impacting investor confidence and future performance.
Risk Assessment
Risk Level: medium — Changes in leadership and compensation can introduce uncertainty about the company's future direction and stability.
Key Players & Entities
- Oragenics, Inc. (company) — Registrant
- September 19, 2024 (date) — Date of Report
FAQ
Who are the specific directors or officers that have departed from Oragenics?
The filing indicates departures but does not list the specific names of the departing directors or officers in the provided text.
What are the key changes in the compensatory arrangements for the officers?
The filing mentions updates to compensatory arrangements but does not provide specific details on the nature of these changes in the provided text.
When was the earliest event reported in this 8-K filing?
The earliest event reported was on September 19, 2024.
What is Oragenics, Inc.'s principal executive office address?
The principal executive offices are located at 1990 Main Street, Suite 750, Sarasota, FL 34236.
What is the SIC code for Oragenics, Inc.?
The Standard Industrial Classification code for Oragenics, Inc. is 2834, Pharmaceutical Preparations.
Filing Stats: 678 words · 3 min read · ~2 pages · Grade level 12.1 · Accepted 2024-09-20 16:11:17
Filing Documents
- form8-k.htm (8-K) — 43KB
- 0001493152-24-037602.txt ( ) — 213KB
- ogen-20240919.xsd (EX-101.SCH) — 3KB
- ogen-20240919_lab.xml (EX-101.LAB) — 33KB
- ogen-20240919_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized on this 20th day of September, 2024. ORAGENICS, INC. (Registrant) BY: /s/Janet Huffman Janet Huffman Chief Financial Officer